Geospatial Access to CAR‑T Clinical Trials for Non‑Hodgkin Lymphoma for Persons With HIV

Cancer research · Diffuse large B-cell lymphoma

Persons living with HIV (PWH) have to travel significantly longer to the nearest CAR‑T clinical trial for non‑Hodgkin lymphoma compared with the general population.

This cross‑sectional study investigates whether persons living with HIV have the same access to chimeric antigen receptor T‑cell (CAR‑T) clinical trial therapy for non‑Hodgkin lymphoma (NHL) as persons without HIV. A total of 254 trials were eligible for review, and 80 met criteria for inclusion with 11 (13.8%) trials including PWH, 58 (72.5%) excluding PWH, and 11 (13.8%) not mentioning HIV. The median population‑weighted travel time was 0.73 (0.36‑1.64) hours for the general population, 1.15 (0.49‑2.38) hours for trials including PWH, and 0.84 (0.40‑1.91) hours for trials excluding PWH. Compared with trials that excluded PWH, trials that included PWH had significantly lower 1‑hour (46.07% vs 55.27%) and 3‑hour (82.22% vs 87.76%) access, and travel time in the South was significantly longer for trials that included PWH compared with trials that excluded PWH. These findings suggest that further efforts are needed to expand access to CAR‑T clinical trials for NHL for PWH.

Access to cutting‑edge CAR‑T therapy is of particular importance for persons living with HIV because NHL is a leading cause of cancer‑attributable deaths among PWH. Disparities in travel time to trials may reduce enrollment and worsen outcomes for this underserved population.

Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.

Original source

Related signals